pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Zioptan
drug
save

tafluprost

Marketedupdated 3mo ago
by Thea Pharma Inc
Approved
community read0 votes

🐶 often sniffed alongside

top 3
  • tagApproval24 co-mentions · 6 sources
  • drugZIOPTAN24 co-mentions · 6 sources
  • companyThea Pharma Inc12 co-mentions · 6 sources

all catalysts(6)

approval · 6
Feb 10, 2012
approval
15y ago
ZIOPTAN (TAFLUPROST) — FDA approval
tafluprost
→
Feb 22, 2013
approval
13y ago
ZIOPTAN (TAFLUPROST) — FDA approval
tafluprost
→
Aug 28, 2013
approval
13y ago
ZIOPTAN (TAFLUPROST) — FDA approval
tafluprost
→
Sep 4, 2015
approval
11y ago
ZIOPTAN (TAFLUPROST) — FDA approval
tafluprost
→
Sep 4, 2015
approval
11y ago
ZIOPTAN (TAFLUPROST) — FDA approval
tafluprost
→
Feb 25, 2026
approval
6mo ago
ZIOPTAN (TAFLUPROST) — FDA approval
tafluprost
→

Trials studying tafluprost

  • phase3A Study of DE-111A on the Treatment of Open Angle Glaucoma or Ocular Hypertensioncompletedn=219

Patent cliff

source: FDA Orange Book
first barrier falls
May 28, 2029
~2.8 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (2)

  • May 28, 2029formulationUS 108641592.8y
  • May 28, 2029formulationUS 99995932.8y

News(0)

no news has mentioned this drug yet

brand
Zioptan
generic
tafluprost
indication
Ocular Hypertension
phase
marketed
Data sources
openFDA · ClinicalTrials.gov
last refreshed 49m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?